Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

4-1-2022

The Role of the Complement System in Chronic Inflammatory
Demyelinating Polyneuropathy: Implications for ComplementTargeted Therapies.
Luis A Querol
Hans-Peter Hartung
Richard A Lewis
Pieter A van Doorn
Timothy R Hammond

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Luis A Querol, Hans-Peter Hartung, Richard A Lewis, Pieter A van Doorn, Timothy R Hammond, Nazem
Atassi, Miguel Alonso-Alonso, and Marinos Dalakas

Neurotherapeutics (2022) 19:864–873
https://doi.org/10.1007/s13311-022-01221-y

REVIEW

The Role of the Complement System in Chronic Inflammatory
Demyelinating Polyneuropathy: Implications for Complement‑Targeted
Therapies
Luis A. Querol1 · Hans‑Peter Hartung2,3,4,5 · Richard A. Lewis6 · Pieter A. van Doorn7 · Timothy R. Hammond8 ·
Nazem Atassi8 · Miguel Alonso‑Alonso8 · Marinos C. Dalakas9,10
Accepted: 12 March 2022 / Published online: 4 April 2022
© The Author(s) 2022

Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common, heterogeneous, immune-mediated neuropathy, characterized by predominant demyelination of motor and sensory nerves. CIDP follows a relapsing–remitting or
a progressive course and causes substantial disability. The pathogenesis of CIDP involves a complex interplay of multiple
aberrant immune responses, creating a pro-inflammatory environment, subsequently inflicting damage on the myelin sheath.
Though the exact triggers are unclear, diverse immune mechanisms encompassing cellular and humoral pathways are
implicated. The complement system appears to play a role in promoting macrophage-mediated demyelination. Complement
deposition in sural nerve biopsies, as well as signs of increased complement activation in serum and CSF of patients with
CIDP, suggest complement involvement in CIDP pathogenesis. Here, we present a comprehensive overview of the preclinical and clinical evidence supporting the potential role of the complement system in CIDP. This understanding furnishes a
strong rationale for targeting the complement system to develop new therapies that could serve the unmet needs of patients
affected by CIDP, particularly in those refractory to standard therapies.
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Chronic inflammatory demyelinating polyneuropathy
(CIDP; sometimes referred to as chronic inflammatory
demyelinating polyradiculoneuropathy) is the most common and heterogeneous, immune-mediated peripheral
neuropathy, typically characterized by predominant
demyelination of motor and sensory nerves. CIDP manifests typically as an insidious onset of weakness, hypo- or
areflexia, numbness, paresthesia, and sensory ataxia with
a progressive or relapsing–remitting pattern [1–3]. The
“typical” CIDP phenotype, characterized by symmetric and
predominantly motor manifestations, is observed in about
50% patients [4]. “Atypical” CIDP, currently redefined as
“CIDP variants,” comprises several well-characterized
entities (multifocal, focal, distal, motor, or sensory CIDP)
[3]. CIDP is closely related to Guillain-Barré Syndrome
(GBS), another immune-mediated peripheral neuropathy
that has an acute onset [5]. The estimated prevalence of
CIDP varies between 0.8 and 10.3 cases per 100,000 people worldwide [6].
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The current standard treatments for CIDP include intravenous immunoglobulins (IVIg), corticosteroids, and plasma
exchange [4]. However, the response to these treatments
remains partial/transient or requires long-term therapy [5].
CIDP is associated with substantial disability and loss of
productivity [6]. An epidemiological study, conducted in
the UK based on 2008 data, found that 32% of patients with
CIDP were unable to walk independently [7]. The significant physical and psychological effects of CIDP markedly
impact the patients’ quality of life [6]. According to a US
nationwide survey in 475 patients with CIDP, 47% had to
stop working due to the disease, and 20% had missed time
from work/school due to symptoms [8]. Furthermore, studies
have reported premature retirement in 14–28% of patients
with CIDP [6].
A diverse and complex interplay of different immunopathological mechanisms, involving cellular, humoral and
complement pathways, culminates in a highly variable pattern of peripheral nerve damage in different clinical variants
of CIDP. Humoral factors and macrophage-mediated demyelination appear to play a crucial role in CIDP [9]; however, the triggers for these aberrant immune responses are
not clearly understood [1, 9]. In some patients, macrophage
infiltration in the myelinated fibers occurs around the nodes
of Ranvier, while in other patients, the internodal region
appears to be involved [2]. Deposition of antibody or complement at peripheral nerve components that distinguish the
nodal regions may act as a trigger for macrophage-induced
demyelination in certain subsets of patients [9].
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In particular, the complement system appears to play an
important role in CIDP pathogenesis. Studies have shown
deposition of complement components, such as C3d and
C9 neoantigen, as well as complement-fixing IgG and IgM
on the myelin sheath in patients with CIDP [10]. Increased
serum and cerebrospinal fluid (CSF) levels of C5a and the
soluble terminal complement complex C5b-C9 have also
been documented in patients with CIDP [11].
Most of the review articles discussing CIDP pathophysiology are focused on macrophage infiltration and demyelination and examined the role of autoantibodies directed to
peripheral nerve components. However, there are no reviews
centered on the role of the complement system in the pathogenesis of CIDP. Considering the current emergence and
success of complement-targeted therapies in other autoimmune disorders, it is important to critically assess the role of
the complement system and the suitability of complementtargeted therapeutics in CIDP patients.

Pathophysiology of CIDP
Cellular and humoral components, including the complement system, are variably involved in peripheral nerve
damage in CIDP (Fig. 1). However, the trigger(s) for the
autoimmune response and the target antigen(s) involved
remain elusive in most patients [12]. Histopathological
changes in CIDP include breakdown of the blood–nerve
barrier (BNB), segmental demyelination near the nodes of

Fig. 1  Role of complement in CIDP pathogenesis
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Ranvier, interstitial edema, and endoneurial inflammatory
cell infiltration, including lymphocytes and macrophages
and varying degrees of admixed axonal damage [1].

Cellular Mechanisms
The involvement of cell-mediated immune mechanisms
in CIDP is substantiated by evidence of T cell activation,
the passage of activated T cells through the BNB, and the
expression of pro-inflammatory cytokines [1]. Conventionally, macrophage and T-cell infiltration in the peripheral
nerves and nerve roots and the subsequent segmental demyelination are believed to be the key cellular changes involved
in CIDP pathogenesis [13].
Increased permeability of the BNB is the primary precursor for nerve inflammation and damage. While the exact
mechanisms remain unknown, adhesion of activated T cells
and upregulation of activation biomarkers and proinflammatory cytokines facilitate the enhanced permeability of the
BNB, thus allowing transfer of macrophages and soluble
factors, such as antibodies and complement including the
C5b-9 membrane attack complex (MAC), to cross the BNB
and exert nerve damage [12]. Furthermore, the severity and
patterns of BNB damage correlate with CIDP phenotypes.
Patients with typical clinical presentation of CIDP seem to
have more severe BNB damage, compared with the other
phenotypes, e.g., patients with typical CIDP have a
prominent reduction in serum claudin-5 levels, a known
paracellular permeability regulator [14]. In addition, there is
a reduction in transendothelial electrical resistance (TEER)
in peripheral nerve microvascular endothelial cells. These
findings correlate with clinical and electrophysiological
severity [14].
Macrophages are involved throughout the pathogenic process in autoimmune neuropathies and play an instrumental
role in CIDP pathophysiology [15]. They are the dominant
infiltrating cell population and cluster around endoneurial
vessels [16]. Complement deposition is one of the facets
of macrophage-mediated damage to neural tissue [17]. The
presence of an array of complement receptors (CRs), including CR1, CR4, C3a anaphylatoxin receptor (C3aR), C5aR1,
and C5aR2 [17] on the macrophages, may help facilitate
myelin sheath damage and phagocytosis by these cells. Incidentally, the C3 receptor is also expressed by other immune
cells, e.g., natural killer (NK) cells, monocytes, granulocytes
[18], and neutrophils. Overall, this interconnection of different elements of the immune system further cements the
role of the complement system in CIDP pathogenesis [19].
Sural nerve biopsies from CIDP patients also show signs
of T cell infiltration [20]. Increased levels of T helper 17
(TH17) cells and expression of retinoic-acid-receptor-related
orphan nuclear receptor gamma (RORγt) have been reported
in the peripheral blood and CSF of patients with active
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CIDP, compared to those with remitting disease [21].
Additionally, patients with typical CIDP exhibit infiltrating CD8+ T cells with monoclonal and oligoclonal restrictions in sural nerve biopsies and peripheral blood [22, 23],
indicating an antigen-driven response and perturbations of
the T cell repertoire. Importantly, the myelinating Schwann
cells in sural nerve biopsies from CIDP patients, but not
the control nerves, express the co-stimulatory molecule
BB-1 and possess the phenotypic markers of antigenpresenting cells [24]. Because their ligands CTLA-4 and
CD28 are also overexpressed on the endoneurial T cells in
the proximity to BB1-positive Schwann cells, the Schwann
cells in CIDP patients have the capacity to function as
professional antigen-presenting cells, possibly presenting
endogenous or phagocytosed myelin antigens to T cells [24,
25].
The presence of cytokines may have implications in damaging the BNB and setting up a chemo-attractive environment for immune cell recruitment and subsequent neural
insult [26]. Higher circulating levels of chemokines [27] and
cytokines [28, 29] were reported in CIDP patients, which
may increase BNB permeability and facilitate lymphoid cell
infiltration. Elevated local expression of cytokines was also
noted. Tumor necrosis factor-alpha (TNF-α), interferongamma (IFN-γ), and interleukin-2 (IL-2) were also observed
within macrophages and T cells in sural nerve biopsies from
CIDP patients.
Although direct evidence for a myelin antigen-specific
auto-reactive T-cell population is currently lacking [30], a
combined role of T cells and macrophages is very likely to
be crucial in CIDP pathogenesis. Activated macrophages
damaging the myelin sheath may lead to the release of other
target molecules with subsequent broadening of autoantigenic epitopes, a process termed epitope spreading
that creates an inflammatory cascade enhancing further the
inflammatory milieus [30]. An interrelated and complex
involvement of various immune components, including
macrophages, T cells, activated antigen-presenting cells,
cytokines, and the complement system, are proposed to be
collectively involved in CIDP pathogenesis [31].
The involvement of T cells in CIDP pathogenesis is well
established; however, the use of T cell-based therapies/
inhibitors has not, to date, been shown to be efficacious in
the management of CIDP. Fingolimod, a first in class sphingosine 1-phosphate receptor modulator that reduces the circulating naïve T- and B-cell population, has shown efficacy
in multiple sclerosis. However, in the FORCIDP study, fingolimod did not demonstrate clinical benefit in CIDP, and
the study was terminated prematurely for futility [32]. There
are multiple reasons, including patient selection and study
design, that may have affected the results, and more evidence
will be required to rule out utility of T cell-based therapies in CIDP management. In addition, controlled trials
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with methotrexate, azathioprine, and interferons have also
been unsuccessful in CIDP [33–35]. Anti B-cell therapies and
therapies that target the neonatal Fc receptor (FcRn) can
offer promising treatment options in CIDP, but further
discussion around them is beyond the scope of this paper.

Humoral Mechanisms
While myelin phagocytosis by macrophages is instrumental
in CIDP pathogenesis, the triggers underlying this process
are not clearly understood. It is postulated that deposition of
autoantibodies specific to peripheral nerve antigens may be
involved, via recognition of the immunoglobulin fragment
crystallizable (Fc) portion or activation of the complement
system [13].
The response to plasma exchange therapy indicates the
important role of circulating factors in CIDP pathogenesis
[12]; however, no specific target antigens have been identified in most patients [20, 31, 36]. Several studies attempted
to elucidate the role of major myelin proteins, which are
known to evoke experimental autoimmune neuritis (EAN),
as the target antigens for autoantibodies in CIDP, but the
results were not definitive [12]. Sera from only a minor
proportion of CIDP patients demonstrated an antibody
response to myelin protein zero (P0), myelin protein 2 (P2),
and peripheral myelin protein (PMP)-22, although IgG antibodies were significantly higher in patients with CIDP than
in controls [37]. Antibodies to acidic glycolipids were also
more frequently seen in CIDP patients [5, 38, 39]. However,
in the majority of these patients, no pathogenic antibodies
are identified.
Antibodies targeting nodes of Ranvier structures have
recently been identified [40–42]. Antibodies against the
paranodal protein contactin-1 (CNTN1) were identified in a
subset of CIDP patients [43]. Antibodies to Caspr1 were also
detected in CIDP patients but not in healthy controls and in
patients with other neuropathies [44]. Further, antibodies to
Caspr1/CNTN1 complex were also recognized in a subset of
CIDP patients with similar serological and clinical manifestations [45]. Antibodies against neurofascin-155 (NF-155), a
glial counterpart of CNTN1, were demonstrated in another
subset of CIDP patients [46]. It is noteworthy that almost
all the antibodies to these paranodal antigens were IgG4, an
IgG subclass that is non-complement fixing [47]. This may
partially explain the lack of treatment response to IVIg treatment in this small subset of CIDP patients who carry these
antibodies [46, 47]. Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability
to fix complement and could potentially be candidates to
complement inhibition [48–51]. A systematic screening of
antibodies revealed a diverse antibody repertoire in CIDP
patients, including those against NF-155 (4.6%), CNTN1
(6.2%), Caspr1/CNTN1 complex (1.5%), P2 (1.6%), and
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anti-ganglioside antibodies (18.6%). In the great majority
of CIDP, patients target antigens of an antibody response
remain still elusive [5, 39, 52, 53]. Such a diverse antibody
profile further strengthens the heterogeneity in CIDP pathogenic mechanisms [20, 31, 40].
Activation of the complement system by autoantibodies may contribute to various mechanisms inflicting
damage to the myelin sheath. One is to facilitate macrophage-mediated myelin phagocytosis, [13], an observation that has been described in a patient with antibodies against the sialosylneolactotetraosylceramide (LM1)
glycolipid [54].
The efficacy of plasma exchange in CIDP further substantiates the role of circulating factors, and potentially that
of the complement system, in the disease pathogenesis [12].
A study using sera obtained from patients with CIDP who
responded to plasma exchange showed binding of IgG and
C3d in 4 of 12 patients [55]. However, complement involvement in certain subgroups of CIDP patients, including those
with non-complement fixing antibodies, is not yet certain
[31, 56].

Role of the Complement Pathway in CIDP
The complement system is an integral part of innate immune
defense and plays an important physiological role in tissue
remodeling [56]. The products of complement activation act
as a link between the innate and the adaptive immune systems, by acting directly on receptors expressed on T cells,
B cells, and macrophages or by modulating dendritic cell
functions.
Complement activation occurs through three different
pathways: classical (C1q), lectin (mannose-binding lectins
or ficolin), and alternative (C3 autoactivation or properdin),
which converge at C3, the most abundant complement protein found in the blood [56]. Subsequently, the effector proteins C3a, C3b, and C5a and the membrane attack complex
(MAC, C5b-9) are generated for target cell lysis [56, 57].
Complement is a complex system, and disruption of its
delicate regulation triggers several autoimmune neurological
disorders [56]. The role of the complement system in various neuropathies and neurodegenerative diseases, including
Guillain–Barré syndrome (GBS), has been well documented.
GBS is an inflammatory demyelinating polyneuropathy
which, due to significantly overlap in electrophysiological, histological, and clinical features, is considered to be
an acute clinical counterpart of CIDP. However, CIDP and
GBS differ in triggers, time course, and response to corticosteroid treatment [20]. In acute inflammatory demyelinating
neuropathy (AIDP), the predominant phenotype of GBS,
an autopsy study showed complement activation and MAC
deposition on Schwann cell membranes [58]. In the animal
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model of experimental autoimmune neuritis, deposition of
MAC preceded demyelination [59]. Moreover, C3 depletion
has been shown to reduce demyelination and inflammation
in experimental allergic neuritis [60, 61]. In acute motor
axonal neuropathy (AMAN), another phenotype of GBS,
Campylobacter jejuni infection-induced autoantibodies have
been found to activate complement and MAC deposition at
the nodes of Ranvier [62].
These data suggest that complement-mediated processes
in peripheral neuropathies are important mediators in their
pathobiology. Hence, the therapeutic approach of targeting
the complement system seems to be viable [31, 63]. In addition, success with complement inhibition with eculizumab
in Myasthenia gravis, an autoimmune neuromuscular condition, [64, 65] encourages exploring this pathway as a potential treatment target in other autoimmune conditions. In the
following sections, we review the preclinical and clinical
evidence regarding the role of complement in CIDP.

Preclinical Evidence of Complement
Involvement in CIDP
Complement plays a role in various autoimmune neuropathies, but much of this data comes from studies on various
animal models of peripheral nerve inflammation [15]. The
EAN rat model is a widely accepted model for GBS, but
some of the inflammatory mechanisms modeled in EAN
are also shared with CIDP [55]. This model has been used
extensively since it replicates pathological hallmarks such as
macrophage-mediated stripping and phagocytosis of compact myelin lamellae, which are observed in CIDP [66]. In
this model, cobra venom factor (CVF), which is known to
deplete C3, was found to reduce EAN severity, possibly
by blocking antigen–antibody complex-induced activation
of complement [60]. Depletion of complement with CVF
reduced clinical scores, demyelination, and inflammation
[61, 67]. The role of complement in autoimmune neuropathies was further validated by administration of soluble CR1,
a natural complement inhibitor that binds and promotes
degradation of C3b and C4b, resulting in suppression of
clinical signs of disease in rats with EAN [68]. Additional
evidence strengthening complement activation in CIDP
includes blockade of nerve conduction with administration
of patient-derived pathogenic IgG with C3 reactivity [55]
and demyelination and conduction blockade due to intraneural administration of patient-derived anti-P0 IgG antibodies
[69].
Evidence is also available on the role of complement in
other animal studies of peripheral neuropathies. In a mice
model of AMAN, inhibition of C1q (with an anti-C1q
antibody) resulted in attenuation of complement cascade
activation and complement deposition, as demonstrated by
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absence of C3c staining or C5b-9 components at the nerve
terminals. There was also evidence of reduced immune cell
recruitment and reduced axonal injury [70].
A novel “Human-in-a-chip” in vitro model, using a
microelectrode array with directed axonal outgrowth over
the electrodes, was recently developed. A human CIDP
model was created by treatment of Schwann cell and motoneuron cultures with CIDP patient-derived serum, which
triggered classical complement pathway activation and, subsequently, the deposition of C3b and C5b-9. Furthermore,
treatment with a test monoclonal antibody inhibitor of C1s,
TNT005, resulted in abrogation of complement deposition
and rescued the electrophysiological deficits [71].

Clinical Evidence of Complement Involvement
in CIDP
Complement involvement in CIDP pathogenesis is also substantiated by several lines of histopathological, serological
and clinical evidence.

Genetic Data
The study of CIDP-related genetic factors remains limited
due to the rarity of the disease and heterogeneity in the
CIDP phenotypes [72]. Cases of CIDP variants have been
described in infants that do not meet the diagnostic criteria
but nevertheless respond to immunomodulatory therapy. A
case series described such CIDP-like illness in five infants
with inherited chronic hemolysis. Although these patients
did not have typical CIDP, the relapsing nature of their disease, demyelination, and improvement in upper limb muscle strength with immunomodulatory treatment mimicked
CIDP. Treatments with IVIg, corticosteroids, rituximab,
and cyclosporine, while failing to prevent relapses, shortened their duration and lessened their severity. Homozygosity mapping, followed by exome sequencing, revealed
a homozygous missense mutation, p.Cys89Tyr, in CD59
(protectin) in all of these patients. Further analysis in four
of five patients (one deceased) revealed that there was a lack
of CD59 expression on red blood cell (RBC) membranes,
monocytes, and lymphocytes. CD59 normally protects host
cells from complement MAC-mediated injury by binding to
C8 and C9 and preventing pore formation in the nerve cell
membrane. C59 deficiency has been associated with demyelination via MAC activation, and MAC is known to play a
vital role in demyelination in early-onset CIDP [73]. Four
pediatric patients with recurrent demyelinating neuropathy
featuring conduction block and p.Cys89Tyr missense mutation in the CD59 gene, unresponsive to IVIg and steroids,
had a dramatic improvement of the neuropathy after eculizumab, a monoclonal antibody preventing activation of C5
and subsequently assembly of the MAC [74]. Overall, the
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CD59 loss of function mutations in case series of patients
with CIDP-like phenotype, along with the response to complement inhibition, suggests a direct link between compliment activation and acquired chronic peripheral nerve
demyelination.
Based on these observations, a hypothesis that de novo
CD59 mutations may be present in patients with sporadic
CIDP was tested. A study performed direct sequencing of
all coding exons of CD59 in 35 adult patients with sporadic
CIDP. However, the p.Cys89Tyr mutation was not identified
in any of the patients. Only one variant, a heterozygous guanine to adenine substitution (c.18G > A), was noted but was
not shown to have any deleterious effect [72]. Considering
the small sample size, these findings cannot completely rule
out CD59 mutation in some rare cases of CIDP, and larger
studies are required to arrive at a definitive conclusion.

Complement Deposition in Nerves
Evidence of complement involvement is supported by
the demonstration of complement deposition in sural
nerve biopsies from CIDP patients. In an early study, sural
nerve biopsy specimens from seven patients with chronic
relapsing demyelinating polyneuropathy showed deposition
of IgM in intraneural blood vessels in all patients and deposition of C3 in six of the seven patients. Deposits of IgM,
but not of C3, were also noted on the Schwann cell plasmalemma of even non-demyelinated nerve fibers in CIDP
patients (Fig. 2A). However, no such deposition was noted
in control patients. These complement-fixing immunoglobulin deposits in intact appearing nerve fibers may contribute
to nerve injury by inducing vascular permeability changes,
thereby increasing BNB permeability, and enhance the
access of antibodies to nerve fibers [10]. In another study,
sural nerve biopsies on specimens from 100 patients with
neuropathy or motor neuron disease were conducted to analyze both C3d and C3c complement components. Among 4
of the 100 patients who had chronic relapsing polyneuropathy, C3d deposition was noted on the surface of some myelin
sheaths in 2 patients [75]. The presence of C3d as a part of
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the immune complex on myelin sheaths suggests a role of
the complement system in the development of neuropathy.
A recent case report of a patient with CIDP demonstrated
presence of a circulating IgG antibody to LM1, but not to
NF-155, CNTN-1, GM1, and GD1b. An immunohistochemical analysis revealed deposition of C9 neoepitope, a component of MAC, on the compact myelin sheath. Macrophage
infiltration was evident with the presence of several CD68positive cells in each fascicle. Furthermore, deposition of
complement was noted at the internodes, which comprise
the majority of the length of myelinated fibers. This case
highlights the role of complement-dependent cytotoxicity
in the pathogenesis of CIDP with anti-LM1 antibodies [54].

Complement Pathway Activation in Serum/CSF
Apart from complement deposition on the myelin sheath,
complement components have also been identified in serum
and CSF samples from patients with CIDP. A study compared serum and CSF levels of C5a and terminal complement complex (TCC) in 21 newly diagnosed, treatmentnaïve CIDP patients, with that of 29 control patients with
noninflammatory neurological diseases. CIDP patients had
significantly higher mean serum and CSF levels of C5a and
TCC than control patients [11]. This is also supported by
the finding of a stable IgG band in the CSF of CIDP patients
suggesting of persistent antigenic stimulation (Fig. 2B) [76,
77]. Results also indicated a systemic rather than local CSF
activation of the complement system in CIDP [11].
Complement components also appear to correlate with
CIDP disease activity. In CIDP patients, systemic terminal
complement activation was associated with residual disease
severity after 4 weeks of IVIg treatment. In 80% of these
patients, inflammatory neuropathy cause and treatment
(INCAT) disability scores were reduced after IVIg treatment
for 4 weeks. CIDP patients with higher disability at the time
of diagnosis tended to have higher serum C5a and soluble
TCC levels; these levels reduced and significantly correlated
with the reduction in INCAT scores at the week 4 follow-up
visit after initiation of IVIg treatment. Larger studies are

Fig. 2  Complement deposition in sural nerve biopsy from CIDP patient (A) and agarose gel electrophoresis patterns of CSF in a patient with
chronic relapsing biopsy (B). A: Reproduced from Dalakas MC and Engel WK [10]; B: Reproduced from Dalakas et al [76]
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warranted to examine terminal complement activation as a
potential surrogate marker for clinical disease activity, progression, and response to immunomodulatory therapies in
patients with major phenotypic variants of CIDP [11].

Complement Involvement in GBS
As noted previously, both GBS and CIDP exhibit similar
patterns of macrophage-mediated demyelination originating
from similar, pathogenic mechanisms [10, 20, 31] like
CIDP, the understanding of immunopathogenesis in GBS
is derived from limited pathological data and acute EAN
models [13]. Hence, evidence of complement involvement
in GBS indirectly strengthens the role of the complement
system in CIDP.
Complement involvement has been implicated among
one of the diverse mechanisms of GBS pathogenesis and
is validated by adequate clinical evidence. The presence of
C3d was reported on the Schwann cell plasma membrane
in myelinated fibers, but not in unmyelinated fibers, in
autopsy studies of three GBS patients. Immunocytochemistry revealed that in many nerve fibers, there was a rim of
C3d and C5b-9 along the outer surface of the Schwann cells.
Further analysis of such C3d-positive fibers revealed mild
vesicular changes in the outermost myelin lamellae [78].
Increased serum TCC levels in GBS patients have been
reported to decline with clinical improvement, becoming
undetectable a month after symptom onset. Membranebound TCC was also found deposited on the abaxonal
Schwann cell surface in a GBS patient [79]. Immunohistochemistry of sural nerve biopsies from five AIDP (a form of
GBS) patients demonstrated C3d or C9 neoepitope deposition in the endoneurium [80]. Similarly, elevated CSF levels
of C3a and C5a have been reported in GBS patients [81].
These findings indicate complement cascade activation due
to binding of specific antibodies to the abaxonal Schwann
cell surface in GBS [78].
The accumulating evidence regarding complement
involvement in many autoimmune neuropathies has generated great interest and encouraged clinical research focused
on complement-targeted therapies in several neurological
disorders [56]. Complement inhibition with eculizumab, a
humanized monoclonal antibody to C5, is currently being
investigated in GBS and has demonstrated some clinical
benefit in phase 2 studies. In one phase 2 study, the
primary efficacy outcome (proportion of patients who reach
functional grade ≤ 2) was not achieved, but a clinical benefit
was observed in secondary efficacy outcomes (proportion
of patients who could run at week 24) [82]. The results of
another phase 2 study were inconclusive considering the
small sample size and severity of disease in enrolled patients
[83]. A phase 3 study to evaluate the efficacy and safety of
eculizumab in GBS (NCT04752566) is ongoing. Additional
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complement inhibitors that target different components of
the pathway are in development [56] and will provide
the opportunity to test the complement’s role in GBS and
CIDP. Two classical pathway inhibitors are in clinical trials for GBS and CIDP. For example, a phase 2/3 study for
ANX005, a C1q inhibitor, in GBS is currently ongoing
(NCT04701164), and a phase 2 study for an inhibitor of
active C1s is also underway in CIDP (NCT04658472).

Discussion/Summary
CIDP is the most prevalent chronic autoimmune neuropathy
and causes substantial disability [6, 20]. The pathogenesis
of CIDP remains elusive, however, a complex interplay of
multiple immunological pathways has been documented.
The available literature on CIDP pathogenesis appears to
be focused on macrophage-mediated demyelination and
attempts to identify autoantibodies. However, a careful
consideration of the observations on complement in various studies highlights an intriguing role for complement in
CIDP pathogenesis (Fig. 1).
A comprehensive review of studies aimed at elucidating the pathogenic mechanisms underlying CIDP reveals
evidence of activation of complement both systemically
and in peripheral nerve. Data from the EAN model-based
preclinical studies has demonstrated reduced severity [60],
demyelination, and inflammation [61, 67] with complement
depletion. Passive transfer of the disease with pathogenic
IgG with complement C3 reactivity from CIDP patients into
rats, resulting in nerve conduction impairment and demyelination [55], and suppression of disease following administration of sCR1 [68], indicates a pathogenetically relevant
association of complement in CIDP patients. Furthermore,
deposition of complement components on patients' nerves
[10, 75], complement-fixing autoantibodies on the myelin
sheath [54], and high systemic complement levels that correlated with disease severity [11] further underscore a role
of complement in CIDP pathophysiology. Complement capture and inhibition are among the mechanisms of action of
IVIg, the currently most effective and widely used therapy
in CIDP [20, 31, 47]. Moreover, genetic mutation leading
to deficiency of CD59, a complement regulator, resulting in
CIDP-like illness in infants [73], provides further supporting evidence. Collectively, these data provide arguments to
invoke complement as a key mediator of nerve dysfunction
and damage in CIDP, at least in a subset of CIDP patients.
The standard of care (SOC) therapies in CIDP, though
effective, have several limitations, such as variable treatment response, side effects with chronic use, need for
venous access, dependency on plasma donations (IVIg)
leading to potentially limited availability, and high patient
burden. Various clinical phenotypes of CIDP appear to
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have similar but not identical, pathogenic causes, which
may explain the variability in treatment response to the
SOC therapies. There is, therefore, a substantial unmet
need in CIDP treatment that requires the development of
alternative therapies that reflect the various disease phenotypes and thereby offers treatments targeted to individual
patients.
The lack of efficacy of fingolimod, a T-cell-based therapy
[32], has encouraged consideration of the complement system and other potential immune mechanisms in CIDP [56].
With its emergence of a likely important role in CIDP, complement has now become an attractive therapeutic target.
Several complement inhibitors, each targeting a specific
step in the complement pathway, are under development,
and clinical studies are ongoing to explore their potential clinical benefits [56, 84]. Eculizumab, a humanized
monoclonal antibody that inhibits C5, has shown clinical benefits in generalized myasthenia gravis [23] and is
currently being investigated in GBS (NCT04752566). A
safety and efficacy study for ANX005, a C1q inhibitor,
in GBS (NCT04701164) is also underway. Furthermore,
an active C1s inhibitor, SAR445088, is currently being
investigated in CIDP (NCT04658472).
Pre-clinical research in CIDP remains limited due to lack
of disease-specific animal models. Conducting clinical trials
is cumbersome due to difficulties in patient recruitment, disease heterogeneity, and the lack of objective biomarkers to
characterize the disease and evaluate response to therapies.
Hence, further clinical research in CIDP can benefit from the
use of novel approaches in study design to overcome these
challenges and ensure solid conclusions when testing new
treatment options in this field.
In summary, considering the drawback of the current
SOC therapies, the preclinical and clinical evidence supporting the role of complement in CIDP pathogenesis, and
the plausible success of early stage complement inhibitors in
diseases other than CIDP, exploring the benefits of complement pathway inhibitors in CIDP is an attractive proposition.
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